Contineum Therapeutics (CTNM) Return on Sales [ROS] (2023 - 2024)
Contineum Therapeutics' Return on Sales [ROS] was -77.24% in Q2 2024, down 155.11 percentage points from 77.87% a year earlier.
Powered by 
Analysis
Contineum Therapeutics (CTNM) Return on Sales [ROS] (2023 - 2024) Analysis & Trends
For FY2023, Return on Sales [ROS] at Contineum Therapeutics came in at 32.15%.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROS (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,348.13 Bn | 1,321.74 Bn | 20.46 Bn | 34.46% |
| 2 | Johnson & Johnson | 675.90 Bn | 595.76 Bn | 17.30 Bn | 24.35% |
| 3 | AbbVie | 519.45 Bn | 487.50 Bn | 13.12 Bn | 36.01% |
| 4 | Merck | 364.95 Bn | 327.95 Bn | 13.19 Bn | 30.74% |
| 5 | Novartis Ag | 311.58 Bn | 285.16 Bn | - | - |
| 6 | Astrazeneca | 289.34 Bn | 262.94 Bn | 13.26 Bn | 29.12% |
| 7 | Amgen | 251.64 Bn | 203.30 Bn | 7.58 Bn | 35.79% |
| 8 | Gilead Sciences | 212.05 Bn | 187.07 Bn | 6.73 Bn | 41.71% |
| 9 | Pfizer | 167.35 Bn | 115.00 Bn | 12.56 Bn | 32.98% |
| 10 | Contineum Therapeutics | 405.40 Mn | -584.86 Mn | - | - |
API Access
Contineum Therapeutics Return on Sales [ROS] API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=CTNM&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "return-on-sales-[ros]", "ticker": "CTNM", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=CTNM&period=max&api_key=YOUR_API_KEY");
const data = await res.json();